These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1300 related articles for article (PubMed ID: 26758542)

  • 1. Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Capranzano P; Capodanno D; Bucciarelli-Ducci C; Gargiulo G; Tamburino C; Francaviglia B; Ohno Y; La Manna A; Antonella S; Attizzani GF; Angiolillo DJ; Tamburino C
    Eur Heart J Acute Cardiovasc Care; 2016 Sep; 5(5):475-86. PubMed ID: 26758542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
    Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.
    Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM;
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-dependent benefits of pre-treatment with new oral P2Y
    Pepe M; Cafaro A; Paradies V; Signore N; Addabbo F; Bortone AS; Navarese EP; Contegiacomo G; Forleo C; Bartolomucci F; Di Cillo O; Bianchi FP; Zanna D; Favale S
    Catheter Cardiovasc Interv; 2019 Mar; 93(4):592-601. PubMed ID: 30269413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
    You J; Li H; Guo W; Li J; Gao L; Wang Y; Geng L; Wang X; Wan Q; Zhang Q
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():598-605. PubMed ID: 31957972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized evaluation of intralesion versus intracoronary abciximab and aspiration thrombectomy in patients with ST-elevation myocardial infarction: The COCTAIL II trial.
    Prati F; Romagnoli E; Limbruno U; Pawlowski T; Fedele S; Gatto L; Di Vito L; Pappalardo A; Ramazzotti V; Picchi A; Trivisonno A; Materia L; Pfiatkosky P; Paoletti G; Marco V; Tavazzi L; Versaci F; Stone GW
    Am Heart J; 2015 Dec; 170(6):1116-23. PubMed ID: 26678633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
    Di Vito L; Versaci F; Limbruno U; Pawlowski T; Gatto L; Romagnoli E; Cattabiani MA; Micari A; Trivisonno A; Marco V; Prati F
    J Cardiovasc Med (Hagerstown); 2016 Sep; 17(9):701-6. PubMed ID: 27467458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.
    Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis.
    Montalescot G; van 't Hof AW; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Collet JP; Goodman SG; Hammett CJ; Huber K; Janzon M; Lapostolle F; Lassen JF; Licour M; Merkely B; Salhi N; Silvain J; Storey RF; Ten Berg JM; Tsatsaris A; Zeymer U; Vicaut E; Hamm CW;
    JACC Cardiovasc Interv; 2016 Apr; 9(7):646-56. PubMed ID: 26952907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting.
    Jin HY; Yang TH; Kim DI; Chung SR; Seo JS; Jang JS; Kim DK; Kim DK; Kim KH; Seol SH; Nam CW; Hur SH; Kim W; Park JS; Kim YJ; Kim DS
    Int J Cardiol; 2013 Sep; 167(5):1877-81. PubMed ID: 22682702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery.
    Ferreiro JL; Homs S; Berdejo J; Roura G; Gómez-Lara J; Romaguera R; Teruel L; Sánchez-Elvira G; Marcano AL; Gómez-Hospital JA; Angiolillo DJ; Cequier Á
    Thromb Haemost; 2013 Jul; 110(1):110-7. PubMed ID: 23615769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-hospital ticagrelor in patients with ST-segment elevation myocardial infarction with long transport time to primary PCI facility.
    Lupi A; Schaffer A; Lazzero M; Tessitori M; De Martino L; Rognoni A; Bongo AS; Porto I
    Cardiovasc Revasc Med; 2016 Dec; 17(8):528-534. PubMed ID: 27666002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial.
    Crimi G; Pica S; Raineri C; Bramucci E; De Ferrari GM; Klersy C; Ferlini M; Marinoni B; Repetto A; Romeo M; Rosti V; Massa M; Raisaro A; Leonardi S; Rubartelli P; Oltrona Visconti L; Ferrario M
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1055-63. PubMed ID: 24156966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study.
    Shavadia J; Welsh R; Gershlick A; Zheng Y; Huber K; Halvorsen S; Steg PG; Van de Werf F; Armstrong PW
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 28525886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Celık T; Balta S; Demır M; Yıldırım AO; Kaya MG; Ozturk C; Demırkol S; Unlu M; Kılıc S; Aydın İ; Iyısoy A
    Cardiol J; 2016; 23(1):84-92. PubMed ID: 26503078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction.
    Vogel RF; Delewi R; Angiolillo DJ; Wilschut JM; Lemmert ME; Diletti R; van Vliet R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Krucoff MW; van Mieghem NM; Smits PC; Vlachojannis GJ
    JACC Cardiovasc Interv; 2021 Jun; 14(12):1323-1333. PubMed ID: 34167672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
    Palmerini T; Calabrò P; Piscione F; De Servi S; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Barozzi C; Tomasi L; Della Riva D; Mariani A; Taglieri N; Reggiani LB; Bianchi R; De Rosa R; Mariani M; Podda G; Généreux P; Stone GW; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1117-27. PubMed ID: 25240538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Monocyte Count on Admission with the Angiographic Thrombus Burden in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Wang Z; Liu N; Ren L; Lei L; Ye H; Peng J
    Arq Bras Cardiol; 2018 Apr; 110(4):333-338. PubMed ID: 29538502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a combination of antiplatelet and antithrombotic pretreatment on myocardial perfusion in patients with an acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.
    Prech M; Bartela E; Janus M; Jeremicz I; Araszkiewicz A; Urbanska L; Pyda M; Grajek S
    Coron Artery Dis; 2016 Nov; 27(7):580-5. PubMed ID: 27228184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.